Leveraging Metabolomics to Assess the Next Generation of Temozolomide-based Therapeutic Approaches for Glioblastomas

作     者：Patrick-Denis St-Coeur Mohamed Touaibia Miroslava Cuperlovic-Culf Pier Jr Morin 

作者机构：Department of Chemistry and Biochemistry Universite' de MonctonMoncton NBE1A3E9 Canada National Research Council of CanadaMoncton NBE1A7R1 Canada 

出 版 物：《Genomics, Proteomics & Bioinformatics》 (基因组蛋白质组与生物信息学报（英文版）)

年 卷 期：2013年第11卷第4期

页      面：199-206,219页

核心收录：

学科分类：0710[理学-生物学] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 0714[理学-统计学（可授理学、经济学学位）] 0703[理学-化学] 100214[医学-肿瘤学] 0701[理学-数学] 0812[工学-计算机科学与技术（可授工学、理学学位）] 10[医学] 

基　　金：the Beatrice Hunter Cancer Research Institute the Brain Tumour Foundation of Canada 

主　　题：Glioblastoma multiformeTemozolomide Signaling cascades Cancer therapeutics Cancer diagnosis 

摘      要：Glioblastoma multiforme （GBM） is the most common adult primary tumor of the cen- tral nervous system. The current standard of care for glioblastoma patients involves a combination of surgery, radiotherapy and chemotherapy with the alkylating agent temozolomide. Several mech- anisms underlying the inherent and acquired temozolomide resistance have been identified and con- tribute to treatment failure. Early identification of temozolomide-resistant GBM patients and improvement of the therapeutic strategies available to treat this malignancy are of uttermost impor- tance. This review initially looks at the molecular pathways underlying GBM formation and devel- opment with a particular emphasis placed on recent therapeutic advances made in the field. Our focus will next be directed toward the molecular mechanisms modulating temozolomide resistance in GBM patients and the strategies envisioned to circumvent this resistance. Finallyl we highlight the diagnostic and prognostic value of metabolomics in cancers and assess its potential usefulness in improving the current standard of care for GBM patients.